ArticleBioMed research international2026
Stratified and Quantified Score Construction of Low-Grade Glioma Samples Based on TP53 Signaling Pathway.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stratified and Quantified Score Construction of Low-Grade Glioma Samples Based on TP53 Signaling Pathway.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study is aimed at distinguishing the phenotypes of low-grade gliomas based on the P53 signaling pathway gene set, revealing the transcriptomic changes in different phenotypes, screening phenotype-related feature genes, constructing a TP53 score, quantitatively describing TP53-related phenotypes, and predicting the response of glioma patients to chemotherapy.
methodsWe obtained transcriptomic sequencing data of low-grade glioma samples from the Cancer Genome Atlas (TCGA) database. Based on the expression levels of genes related to prognosis in the P53 signaling pathway, we performed consensus clustering on glioma samples to describe sample heterogeneity. Through differentially expressed genes (DEGs), we showed the transcriptomic changes between different TP53 phenotypes. We used univariate COX analysis to remove redundant information and retain prognostic factors. We used principal component analysis to retain the first principal component of the prognostic factors as the TP53 score. We elucidated the correlation between the TP53 score and mRNAsi, immune cell subtypes, and EMT markers.
resultsWe obtained the TP53 genes and screened 14 prognostic risk factors through univariate COX analysis. Based on prognostic risk factors, we classified glioma samples into TP53 clusters using consensus clustering, describing sample heterogeneity. The prognosis and immune cell microenvironment characteristics differed between TP53 clusters. Among the DEGs between TP53 clusters, we screened 38 as prognostic factors. We used the first principal component of these 38 genes as the TP53 score. The TP53 score was positively correlated with immune cell subtypes and EMT markers and negatively correlated with mRNAsi. High TP53 glioma samples were more sensitive to vorinostat, elesclomol, gefitinib, AICAR, axitinib, and bosutinib.
conclusionThe TP53 score based on the P53 signaling pathway can describe the heterogeneity of glioma samples and distinguish different immune microenvironment characteristics and prognostic features. A high TP53 score indicates more active epithelial-mesenchymal transition and lower tumor stemness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.